Redirecting to original paper in 30 seconds...
Click below to go immediately or wait for automatic redirect
📄 Abstract
Abstract: We propose two novel loss functions, Multiplicative Loss and
Confidence-Adaptive Multiplicative Loss, for semantic segmentation in medical
and cellular images. Although Cross Entropy and Dice Loss are widely used,
their additive combination is sensitive to hyperparameters and often performs
suboptimally, especially with limited data. Medical images suffer from data
scarcity due to privacy, ethics, and costly annotations, requiring robust and
efficient training objectives. Our Multiplicative Loss combines Cross Entropy
and Dice losses multiplicatively, dynamically modulating gradients based on
prediction confidence. This reduces penalties for confident correct predictions
and amplifies gradients for incorrect overconfident ones, stabilizing
optimization. Building on this, Confidence-Adaptive Multiplicative Loss applies
a confidence-driven exponential scaling inspired by Focal Loss, integrating
predicted probabilities and Dice coefficients to emphasize difficult samples.
This enhances learning under extreme data scarcity by strengthening gradients
when confidence is low. Experiments on cellular and medical segmentation
benchmarks show our framework consistently outperforms tuned additive and
existing loss functions, offering a simple, effective, and hyperparameter-free
mechanism for robust segmentation under challenging data limitations.
Key Contributions
This paper introduces two novel loss functions, Multiplicative Loss and Confidence-Adaptive Multiplicative Loss, for semantic segmentation in medical and cellular images. These losses multiplicatively combine Cross Entropy and Dice losses, dynamically modulating gradients based on prediction confidence to stabilize optimization and improve performance, especially with limited data.
Business Value
Improving semantic segmentation accuracy in medical and cellular images can lead to more precise diagnoses, better treatment planning, and accelerated drug discovery, ultimately improving patient outcomes and research efficiency.